|
NAME: John Schindler, Ph.D.
POSITION TITLE: Assistant Professor, Cancer Immunobiology Center
INSTITUTION AND LOCATION DEGREE
(if applicable) YEAR(s) FIELD OF STUDY
Brown University, Providence, RI B.S. 1968 Chemistry
Massachusetts Institute of Technology Ph.D. 1978 Biochemistry
B. Selected peer-reviewed publications (in chronological order). Do not include publications submitted or in preparation.
PUBLICATIONS (1995 2002; 14 total):
Sausville, E.A., Headlee, D., Stetler-Stevenson, M., Jaffe, E.S., Solomon, D., Figg, W.D., Herdt, J., Kopp, W.C., Rager, H., Steinberg, S.M., Ghetie, V., Schindler, J., Uhr, J., Wittes, R.E. and Vitetta, E.S. Continuous infusion of the Anti-CD22 immunotoxin, IgG-RFB4-SMPT-dgA in patients with B cell lymphoma: a Phase I study. Blood, 85:3457-3465, 1995.
Stone, M., Sausville, E., Headlee, D., Lucas, E., Figg, W., Stetler-Stevenson, M-A., Jaffe, E., Solomon, D., Lush, R., Senderowitz, A., Ghetie, V., Schindler, J., Uhr, J., and Vitetta, E.S. A Phase I study of bolus vs. continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA in patients with B cell lymphoma. Blood, 88(4):1188-1197, 1996.
Engert, A., Schnell, R., Schindler, J., Radszuhn, A., Hatwig, M-T., Drillich, S., Schon, G., Bohlen, H., Tesch, H., Hansmann, M-L., Barth, S., Ghetie, V., Uhr, J., Diehl, V. and Vitetta, E. A phase I-study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood, 89(2):403-410, 1997.
Schnell, R., Vitetta, E., Schindler, J., Ghetie, V., Hell, K., Borchmann, P., Barth, S., Drillich, S., Diehl, V. and Engert, A. A phase II multicenter trial of bolus infusion of the anti-CD25 ricin A-chain immunotoxin RFT5-dgA in patients with refractory Hodgkins lymphoma. Leukemia & Lymphoma, 30:5-6:525-537, 1998.
Schnell, R., Vitetta, E., Schindler, J., Borchmann, P., Barth, S., Ghetie, V., Hell, K., Drillich, S., Diehl, V. and Engert, A. Treatment of refractory Hodgkins lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leukemia, 14:1:129-135, 2000.
Messmann, R.A., Vitetta, E.S., Headlee, D., Senderowicz, A.M., Figg, W.D., Schindler, J., Michiel, D.F., Creekmore, S., Steinberg, S.M., Kohler, D., Jaffe, E.S., Stetler-Stevenson, M., Chen, H., Ghetie, V. and Sausville, E.A. A phase I study of combination therapy with immunotoxins IgG-HD37-dgA and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B-cell lymphoma. Clinical Cancer Research, 6(4):1302-13, 2000.
Schindler J., Sausville, E., Messmann, R., Uhr, J.W., and Vitetta, E.S. The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with Non-Hodgkins lymphoma is exacerbated by prior radiotherapy: A retrospective analysis of patients in five clinical trials. Clinical Cancer Research, 7:255-258, 2001.
Andre-Schmutz, I., Le Deist, F., Hacein-Bey, S., Vitetta, E., Schindler, J., Chedeville, G., Vilmer, E., Fischer, A. and Cavazzana-Calvo, M. . Improving immune reconstitution without GVHD following hematopoietic stem cell transplantation by infusion of donor T lymphocytes ex vivo depleted of alloreactive cells by a CD25-specific immunotoxin Lancet, 360:130-137, 2002. |
